A finger splint for manual therapy according to the present invention comprises: a base sheet made of a metal material and of a certain length and width to surround a finger; a base hole formed through the center of the base sheet in a rhombus shape; a first hole extending through both upper left and right sides of the base hole along a portion of a periphery of the finger; and a second hole extending through both lower left and right sides of the base hole along the periphery of the finger to correspond to the position and size of the first hole. The finger splint for manual therapy according to the present invention has the effect of providing an excellent and comfortable fit on the basis of an ergonomic structure as well as sufficiently ensuring a basic fixing force.

The invention is destined for creation of pharmaceutical compositions ensuring restoring the physiological processes of cells and all the organism in whole due to ROS formation in the organism, and is characterized by presence of cyclic maltooligosaccharides, cyclodextrins, used in amount 0.001-99.9 mass % in combination with aqueous solution of stable suspension of heterocrystals of titanium dioxide or silicon dioxide particles with size no less than 450 nm and content in amount of 0.0001-5% mass, having on the surface of crystals and particles in the energy centers electronically-excited triplet oxygen 3O2 up to 80%.

In the structure of pharmaceutical composition active pharmaceutical ingredients and pharmaceutically acceptable additions are additionally included in amount 0.0001-99.0% mass.

Pharmaceutical composition additionally comprises cytostatic Doxorubicin taken in amount from 0.0001 up to 0.001 mg/ml for intramuscular administering. Medical agent, comprising pharmaceutical composition, ensures therapeutically significant effect for restoring physiological processes in organism.

The invention is destined for creation of pharmaceutical compositions ensuring restoring the physiological processes of cells and all the organism in whole due to ROS formation in the organism, and is characterized by presence of cyclic maltooligosaccharides, cyclodextrins, used in amount 0.001-99.9 mass % in combination with aqueous solution of stable suspension of heterocrystals of titanium dioxide or silicon dioxide particles with size no less than 450 nm and content in amount of 0.0001-5% mass, having on the surface of crystals and particles in the energy centers electronically-excited triplet oxygen 3O2 up to 80%.

In the structure of pharmaceutical composition active pharmaceutical ingredients and pharmaceutically acceptable additions are additionally included in amount 0.0001-99.0% mass.

Pharmaceutical composition additionally comprises cytostatic Doxorubicin taken in amount from 0.0001 up to 0.001 mg/ml for intramuscular administering. Medical agent, comprising pharmaceutical composition, ensures therapeutically significant effect for restoring physiological processes in organism.

Medical devices having a controller in operative communication with a polymeric nanocomposite treatment device are disclosed. The polymeric nanocomposite treatment device includes a layered construction having a top layer and a bottom layer both comprising a matrix variable density polytetrafluoroethylene, a layer of carbon nanostructures juxtaposed to one each of the top layer and the bottom layer, and an electronic network layer between the two layers of carbon nanostructures. The electronic network layer comprises a quantum micro-chiplet QMC or an octagonal quantum micro-chiplet integrated with a photonic integrated circuit.

Medical devices having a controller in operative communication with a polymeric nanocomposite treatment device are disclosed. The polymeric nanocomposite treatment device includes a layered construction having a top layer and a bottom layer both comprising a matrix variable density polytetrafluoroethylene, a layer of carbon nanostructures juxtaposed to one each of the top layer and the bottom layer, and an electronic network layer between the two layers of carbon nanostructures. The electronic network layer comprises a quantum micro-chiplet QMC or an octagonal quantum micro-chiplet integrated with a photonic integrated circuit.

This invention relates to a hybrid fabric comprising at least one structural fiber having a first melting temperature range and at least one thermo-formable fiber of having a second melting temperature range which is lower than the first melting temperature range to such an extent that the structural fiber does not melt in the second melting temperature range of the thermo-formable fiber. The hybrid fabric comprises (1) a first network comprising the structural fibers, (2) a second network comprising the thermo-formable fibers, the thermo-formable fibers comprising non-relaxed fibers made of a thermoplastic material, and (3) a plurality of openings between the fibers of the first and second network. The structural and thermo-formable fibers of respectively the first and second network interpenetrate one another and are connected to each other over at least part of the first and second network at a plurality of knot positions in the fabric where the structural and thermo-formable fibers are interwoven.

This invention relates to a hybrid fabric comprising at least one structural fiber having a first melting temperature range and at least one thermo-formable fiber of having a second melting temperature range which is lower than the first melting temperature range to such an extent that the structural fiber does not melt in the second melting temperature range of the thermo-formable fiber. The hybrid fabric comprises (1) a first network comprising the structural fibers, (2) a second network comprising the thermo-formable fibers, the thermo-formable fibers comprising non-relaxed fibers made of a thermoplastic material, and (3) a plurality of openings between the fibers of the first and second network. The structural and thermo-formable fibers of respectively the first and second network interpenetrate one another and are connected to each other over at least part of the first and second network at a plurality of knot positions in the fabric where the structural and thermo-formable fibers are interwoven.

Disclosed herein are antimicrobial elastic support bandages including a plurality of warp threads extending along at least a portion of the length thereof and including non-antimicrobial warp regions and antimicrobial warp regions arranged in an alternating fashion across the width thereof, wherein (a) a non-antimicrobial warp region comprises an elastic material that is stretchable in the direction of the length, (b) an antimicrobial warp region comprises (i) a flexible fiber coupled to an antimicrobial metal, and (ii) an elastic material that is stretchable in the direction of the length, wherein the flexible fiber is coupled to the elastic material, and (c) at least a portion of the warp threads are separated by about 3 microns to about 20 microns; and further including a plurality of weft threads extending across at least a portion of the width and comprising a biocompatible material, wherein at least some of the weft threads are separated by about 3 microns to about 20 microns, wherein at least a portion of the warp threads are interwoven with at least a portion of the weft threads.

Disclosed herein are antimicrobial elastic support bandages including a plurality of warp threads extending along at least a portion of the length thereof and including non-antimicrobial warp regions and antimicrobial warp regions arranged in an alternating fashion across the width thereof, wherein (a) a non-antimicrobial warp region comprises an elastic material that is stretchable in the direction of the length, (b) an antimicrobial warp region comprises (i) a flexible fiber coupled to an antimicrobial metal, and (ii) an elastic material that is stretchable in the direction of the length, wherein the flexible fiber is coupled to the elastic material, and (c) at least a portion of the warp threads are separated by about 3 microns to about 20 microns; and further including a plurality of weft threads extending across at least a portion of the width and comprising a biocompatible material, wherein at least some of the weft threads are separated by about 3 microns to about 20 microns, wherein at least a portion of the warp threads are interwoven with at least a portion of the weft threads.

Embodiments of the disclosure include elastomeric stretch fibers containing an anti-tack agent, methods of preparing the fiber, methods of using this fiber, articles including this fiber, and the like.